This section covers all aspects of preclinical investigations on therapeutic agents. It welcomes submissions concerning anti-cancer drug discovery and development, and targeted therapies.
Smac mimetics LCL161 and GDC-0152 inhibit osteosarcoma growth and metastasis in mice
Current therapies fail to cure over a third of osteosarcoma patients and around three quarters of those with metastatic disease. “Smac mimetics” (also known as “IAP antagonists”) are a new class of anti-cancer...
Citation: BMC Cancer 2019 19:924